Psychotropic Medication in Intellectual and Developmental Disabilities: Patterns of Use and Recommendations for Monitoring Effects
- 19 Downloads
Purpose of Review
The purpose of this paper is to provide a brief review of the patterns of psychotropic medication use in individuals with intellectual and developmental disabilities (IDD) and recommendations for monitoring the effects of these medications.
Challenging behavior (e.g., aggression, self-injury, property destruction) in individuals with IDD is often observed, and both behavioral and pharmacological interventions have been evaluated for their effectiveness in treating these behaviors. Although behavioral interventions have been shown to be effective at decreasing challenging behavior, psychotropic medications are frequently used to treat challenging behavior despite a lack of clinical indication (i.e., psychiatric diagnosis).
Limited evidence exists supporting the effectiveness of psychotropic medication to address challenging behavior. Given the demonstrated effectiveness of behavioral interventions, a comprehensive approach to supporting those with IDD and challenging behavior should include behavioral assessment and intervention, and continuous monitoring of and data collection on challenging behavior.
KeywordsPsychotropic medication Intellectual and developmental disabilities Challenging behavior
Compliance with Ethical Standards
Conflict of Interest
Maria Valdovinos declares that she has no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Lee CS, Williamson LR, Martin SE, DeMarco M, Majczak M, Martini J, et al. Adverse events in very young children prescribed psychotropic medications: preliminary findings from an acute clinical sample. J Child Adolesc Psychopharmacol. 2015;25. https://doi.org/10.1089/cap.2015.0034.CrossRefGoogle Scholar
- 12.Kreider AR, Matone M, Bellonci C, dos Reis S, Feudtner C, Huang YS, et al. Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children. J Am Acad Child Adolesc Psychiatry. 2014;53:960–970.e2. https://doi.org/10.1016/j.jaac.2014.05.010.CrossRefPubMedGoogle Scholar
- 14.McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry. 2015;15:303–13. https://doi.org/10.1186/s12888-015-0688-2.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Rasmussen L, Pratt N, Roughead E, Moffat A. Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: a drug utilization study based on children enrolled in the longitudinal study of Australian children. J Autism Dev Disord. 2019;49:227–35. https://doi.org/10.1007/s10803-018-3718-3.CrossRefPubMedGoogle Scholar
- 20.Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015;351:h4326. https://doi.org/10.1136/bmj.h4326.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.• Perry BI, Kwok HF, Mendis J, Purandare K, Wijeratne A, et al. Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey. J Intellect Disabil Res. 2018;62:140–9. https://doi.org/10.1111/jir.12471Identified a pattern of psychotropic medication prescription to address challenging behavior, rather than psychopathology, and factors that may attribute to this pattern. CrossRefPubMedGoogle Scholar
- 28.O’Dwyer C, McCallion P, Henman M, McCarron M, O’Leary E, Burke E, et al. Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities. J Appl Res Intellect Disabil. 2019;32:981–93. https://doi.org/10.1111/jar.12591.CrossRefPubMedGoogle Scholar
- 29.Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intellect Disabil Res. 2011;55:665–74. https://doi.org/10.1111/j.1365-2788.2011.01421.x.CrossRefGoogle Scholar
- 31.Deb S, Unwin G, Deb T. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. 2015;59:11–25. https://doi.org/10.1111/jir.12119.CrossRefPubMedGoogle Scholar
- 33.Scheifes A, Walraven S, Stolker JJ, Nijman HL, Egberts TC, Heerdink ER. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behavior using psychotropic drugs. Res Dev Intellect Disabil. 2016;49-50:13–21. https://doi.org/10.1016/j.ridd.2015.11.017.CrossRefGoogle Scholar
- 34.Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110–9. https://doi.org/10.1097/CHI.0b013e3181b76658.CrossRefPubMedGoogle Scholar
- 36.Unwin GL, Deb S. Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. Res Dev Disabil. 2011;32:2121–33. https://doi.org/10.1002/14651858.CD000377.pub2.CrossRefPubMedGoogle Scholar
- 37.Sohanpal SK, Deb S, Thomas C, Soni R, Lenôtre L, Unwin G. The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. J Intellect Disabil Res. 2007;51:750–65. https://doi.org/10.1111/j.1365-2788.2006.00935.x.CrossRefPubMedGoogle Scholar
- 38.Handen BL, Aman MG, Arnold LE, Hyman SL, Tumuluru RV, Lecavalier L, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:905–15. https://doi.org/10.1016/j.jaac.2015.08.013.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina B, Findling RL, et al. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. J Child Adolesc Psychopharmacol. 2015;25:225–33. https://doi.org/10.1089/cap.2014.0097.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Ruddick L, Davies L, Bacarese-Hamilton M, Oliver C. Self-injurious, aggressive and destructive behaviour in children with severe intellectual disability: prevalence and service need and service receipt in the UK. Res Dev Disabil. 2015;45-46:307–15. https://doi.org/10.1016/j.ridd.2015.07.019.CrossRefPubMedGoogle Scholar
- 41.Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. Am Acad Child Adolesc Psychiatry. 2009;48:1143–54. https://doi.org/10.1097/CHI.0b013e3181bfd669.CrossRefGoogle Scholar
- 42.Valdovinos MG, Henninger-McMahon M, Schieber E, Beard L, Conley B, Haas A. Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. Int J Dev Disabil. 2016;62:200–11. https://doi.org/10.1080/20473869.2016.1177301.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Valdovinos MG, Nelson SM, Kuhle J, Dierks AM. Using analogue functional analysis to measure variations in problem behavior rate and function after psychotropic medication changes: a clinical demonstration. J Ment Health Res Intellect Disabil. 2009;2:279–93. https://doi.org/10.1080/19315860903104807.CrossRefGoogle Scholar
- 49.Zarcone JR, Lindauer SL, Morse PS, Crosland KA, Valdovinos MG, McKerchar TL, et al. Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. Am J Ment Retard. 2004;109:310–21. https://doi.org/10.1352/0895-8017(2004)109%3C310:EORODB%3E2.0.CO;2.CrossRefPubMedGoogle Scholar
- 55.O’Dwyer M, Peklar J, McCallion P, McCarron M, Henman MC. Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study. BMJ Open. 2016;6:e010505. https://doi.org/10.1136/bmjopen-2015-010505.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.• Valdovinos MG, Schieber E, Henninger-McMahon M, Beard L, Wilkinson A, Carpenter J. Adverse side effects of psychotropic medication and challenging behavior: pilot work assessing impact. J Dev Phys Disabil. 2017;29:969–82. https://doi.org/10.1007/s10882-017-9570-0Proposes a method to evaluate the potential relationship between adverse side effects and challenging behavior. CrossRefPubMedPubMedCentralGoogle Scholar
- 61.•• de Kuijper G, van der Putten AAJ. Knowledge and expectations of direct support professionals toward effects of psychotropic drug use in people with intellectual disabilities. J Appl Res Intellect Disabil. 2017;30:1–9S. https://doi.org/10.1111/jar.12357Found that direct support professionals’ knowledge and expectations of how psychotropic medications impact behavior of individuals with IDD are not realistic; they provide some recommendations for training. CrossRefPubMedGoogle Scholar
- 62.Oliver MNI, Skillman GD. Optimizing direct-care paraprofessionals’ adherence to behavioral support programs. NADD Bull. 2012;5(1).Google Scholar
- 64.• Li A, Poling A. Board certified behavior analysts and psychotropic medications: slipshod training, inconsistent involvement, and reason for hope. Behav Anal Pract. 2018;11:350–7. https://doi.org/10.1007/s40617-018-0237-9Identified gaps in behavior analysts’ training regarding psychotropic medication and recommend areas to develop competence. CrossRefPubMedPubMedCentralGoogle Scholar
- 65.•• Molina-Ruiz RM, Martín-Carballeda J, Asensio-Moreno I, Montañés-Rada F. A guide to pharmacological treatment of patients with intellectual disability in psychiatry. Int J Psychiatry Med. 2017;52:176–89. https://doi.org/10.1177/0091217417720896Conducted a brief review of the effectiveness of treatment with psychotropic medication and provide recommendations for psychotropic medication use. CrossRefPubMedGoogle Scholar
- 67.Carr EG, Smith CE, Giacin TA, Whelan BM, Pancari J. Menstrual discomfort as a biological setting event for severe problem behavior: assessment and intervention. Am J Ment Retard. 2003;108:117–33. https://doi.org/10.1352/0895-8017(2003)108<0117:MDAABS>2.0.CO;2.CrossRefPubMedGoogle Scholar